Effect of itopride, a new prokinetic, in patients with mild GERD: A pilot study

Table 1 Clinical characteristics of patients

	150 mg		300 mg	P
Age (yr)		44 ± 9	45 ± 12	0.8141
Sex	Male	7	5	0.734
	Female	6	8
Weight		64 ± 11	61 ± 12	0.4281
Duration of reflux disease	< 6 mo	5	2	0.412
	6 -2 yr	6	8
	> 2 yr	2	3
Pre-medication	Yes	2	1	0.828
	No	11	12
Endoscopy	0	5	7	0.717
(Savary-Miller grade)
	I	7	5
	II	1	1
Drinking	Yes	2	3	0.884
	No	11	10
Smoking	Yes	3	3	1
	No	10	10

P value by χ² test except for ¹two sample t-test.

Table 2 Changes of acid reflux variables and DeMeester score in 26 patients with GERD after treatment with 150 or 300 mg of itopride

Variable	Group (mg/d)	Itopride Tx.	n	Mean	SD	P
Number of acid refluxes	150	Pre	12	99.25	88.57	0.97
		Post	12	76.92	60.53
	300	Pre	13	150.77	246.15	0.057
		Post	13	52.23	39.79
Number of acid refluxes longer than 5 min	150	Pre	12	6.08	5.32	0.287
		Post	12	3.83	5.32
	300	Pre	13	6.23	5.12	0.054
		Post	13	2.69	2.5
Longest time acid refluxes (min)	150	Pre	12	30.55	33.37	0.018
		Post	12	14.09	11.03
	300	Pre	13	30.25	56.4	0.289
		Post	13	20.78	33.64
Total time below pH 4 (min)	150	Pre	12	138.42	98.56	0.16
		Post	12	92.09	78.07
	300	Pre	13	145.08	86.1	0.011
		Post	13	71.77	51.43
Fraction time below pH 4 (%)	150	Pre	12	11.13	9.26	0.211
		Post	12	10.12	12.69
	300	Pre	13	11.2	6.69	0.005
		Post	13	5.27	3.57
DeMeester score	150	Pre	12	32.5	16.96	0.16
		Post	12	22.89	18.75
	300	Pre	13	44.48	37.5	0.007
		Post	13	19.56	14.72